The market size of the Global Clinical Trial Planning And Design Services Market is predicted to show an 8.27% CAGR during the forecast period of 2022-30. The clinical trial is a protocol that studies new treatments and tests and checks their effects on human health. The clinical trial planning and design services offer data accuracy, adaptability, consistency, and compliance to clinical studies. Pharmaceutical companies use clinical trial planning and design services during the drug development process or molecular analysis of generics and biosimilars.
The factors such as increasing use of clinical trial management services, adoption of advanced medical technologies, and rising government investments for research and development of clinical trial protocols are expected to boost the market growth over the forecast period. Furthermore, increased R&D expenditure by the pharma and biotech companies and the rising prevalence of chronic and infectious diseases are fueling the growth of the clinical trial planning and design services market. Leading players are emphasizing on global expansion in order to gain a huge market share. For instance, in Sept 2022, Cytel Inc.'s business expanded across the Asia-Pacific area (APAC). This makes Cytel's existing biometrics and advanced statistical solutions more accessible to APAC biotech and biopharma enterprises. Cytel now has offices in Australia, Shanghai, Beijing, and Singapore, with ambitions to grow into Seoul and Tokyo in the future. This expansion is the latest move in Cytel's mission to provide advanced analytics capabilities to drug developers worldwide.However, the high cost of devices with advanced technologies and poor reimbursement policies may downscale the market growth during 2020-2030.
The clinical trial planning and design services market is segmented based on trial phases, therapeutic areas, services, and regions. The Trial Phases segment is divided into Phase I, Phase II, Phase III, and Phase IV. Based on the therapeutic area, the market is divided into oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas. The oncological disorders segment is the fastest-growing segment of the clinical trial planning and design market due to the rising prevalence of cancer. Furthermore, the neurological disorders segment is anticipated to boost the market, owing to the rise in neurology clinical trials. By Services, the market is segmented into statistical analysis plan, eCRF, site identification and selection, medical writing, and other services.
Based on the region, the clinical trial planning and design services market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. In 2021, North America dominated the clinical trial planning and design services market. The large share of the North American regional segment can be attributed to the increasing number of pharmaceutical companies, rising adoption of advanced medical technologies, and high clinical R&D investments by the government.
Some of the key players operating in the clinical trial planning and design services market are Atlantia Clinical Trials, PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences, LLX Solutions, SGS, ADM Korea, McDougall Scientific, ClinAsia, BioPoint, IQVIA, PPD, Inc., Veristat, LLC, Clinical Accelerator, Allied Clinical Management GmbH, Parexel International Corporation, Pepgra, WIRB-Copernicus Group, and other.
- Atlantia Clinical Trials
- Emergo UL
- Health Policy Associate
- CD BioSciences
- LLX Solutions
- ADM Korea
- McDougall Scientific
- PPD, Inc.
- Veristat, LLC
- Clinical Accelerator
- Allied Clinical Management GmbH
- Parexel International Corporation
- WIRB-Copernicus Group
- Other Prominent Players